Results 41 to 50 of about 17,525 (157)
IGF-1R regulation of colon cancer stem cells
Regulatory Peptides, 2010 Despite recent advances in therapeutics, recurrence of colon cancer occurs in 50% of the cases, which could partly be due to the presence of self renewing cancer stem‐like cells (CSCs) which are resistant to chemotherapy.
Adhip PN Majumdar +3 more
openaire +1 more source
Fluorescent-Antibody Targeting of Insulin-Like Growth Factor-1 Receptor Visualizes Metastatic Human Colon Cancer in Orthotopic Mouse Models. [PDF]
PLoS ONE, 2016 Fluorescent-antibody targeting of metastatic cancer has been demonstrated by our laboratory to enable tumor visualization and effective fluorescence-guided surgery.
Jeong Youp Park +5 more
doaj +1 more source
Revisiting the IGF-1R as a breast cancer target [PDF]
npj Precision Oncology, 2017 AbstractThe type I insulin-like growth factor-1 receptor is a well-described target in breast cancer and multiple clinical trials examining insulin-like growth factor-1 receptor have been completed. Unfortunately, monoclonal antibodies and tyrosine kinase inhibitors targeting insulin-like growth factor-1 receptor failed in phase III breast clinical ...
Roudy Chiminch Ekyalongo, Douglas Yee
openaire +3 more sources
Cells, 2020 Triple-negative breast cancer (TNBC) is an aggressive breast tumor subtype that currently lacks targeted treatment options. The role played by the insulin-like growth factor-1 (IGF-1) and its cognate receptor IGF-1R in TNBC has been reported ...
Damiano Cosimo Rigiracciolo +7 more
doaj +1 more source
Gut and Liver, 2022 Background/Aims: Gallbladder cancer is fatal, but fluorescent imaging technology can facilitate timely diagnosis and improve patient outcomes. Fluorophore-conjugated insulin-like growth factor-1 receptor (IGF-1R) targeted antibodies were used to ...
Jung Ha Choi, Jeong Youp Park
doaj +1 more source
IGF-1R as an anti-cancer target--trials and tribulations [PDF]
Chinese Journal of Cancer, 2013 Type I insulin-like growth factor receptor (IGF-1R) has long been recognized for its role in tumorigenesis and growth, but only recently have the tools for targeting the IGF pathway become available. More than 10 IGF/IGF-1R inhibitors have entered clinical trials, and these belong to three main classes: (1) monoclonal antibodies against IGF-1R, (2 ...
Chen, Helen X., Sharon, Elad
openaire +2 more sources
Oncotarget, 2015 Identifying patients who may benefit from targeted therapy is an urgent clinical issue in prostate cancer (PCa). We investigated the molecular relationship between TMPRSS2-ERG (T2E) fusion gene and insulin-like growth factor receptor (IGF-1R) to optimize the use of IGF-1R inhibitors.IGF-1R was analyzed in cell lines and in radical prostatectomy ...
Mancarella, C +9 more
openaire +4 more sources
Advanced Science, EarlyView.IGF‐1 deficiency underlies poor ovarian response (POR), as reduced levels in follicular fluid and granulosa cells impair antral follicle formation and compromise reproductive outcomes. Including IGF‐1 as a biomarker significantly enhances the accuracy of models predicting both PORrisk and pregnancy success.
Zhu Hu +9 more
wiley +1 more source
Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells. [PDF]
PLoS ONE, 2017 BACKGROUND:Triple-negative breast cancer (TNBC) is the most intractable type of breast cancer, and there is a lack of effective targeted therapy. Insulin-like growth factor-1 receptor (IGF-1R) is reportedly a potential target for TNBC treatment. However,
Weibin Wu +7 more
doaj +1 more source
Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma
Advanced Science, EarlyView.Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian +7 more
wiley +1 more source